Janus Kinase V617F mutation in cigarette smokers

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• The JAK2 V617F mutation is a primary driver of polycythemia vera (PV), causing overactive erythropoietin receptor signaling.
• This mutation has also been observed in individuals without PV, including healthy people.
• Smoking is a known cause of secondary polycythemia, prompting an investigation into its relationship with the JAK2 mutation.

Purpose of the Study:

• To investigate the effect of smoking on the prevalence and frequency of the JAK2 V617F mutation.
• To explore the correlation between the JAK2 mutation and erythrocytosis in smokers versus nonsmokers.

Main Methods:

• A case-control study involving hospitalized smokers (n=81) and nonsmokers (n=61).
• Analysis of serum for complete blood count, erythropoietin, ferritin, and venous blood gases.
• Detection of JAK2 mutation using highly sensitive allele-specific Quantitative Real Time PCR.

Main Results:

• The JAK2 mutation was significantly more prevalent in smokers (35.8%) compared to nonsmokers (14.8%) (P = 0.007).
• The frequency of the JAK2 mutation was higher in smokers (mean 6.78 × 10⁻⁴) than in nonsmokers (mean 1.51 × 10⁻⁴) (P = 0.027).
• Smokers exhibited higher hematocrit levels, but no direct correlation with the JAK2 mutation was found.

Conclusions:

• Smoking is associated with a higher prevalence and frequency of the JAK2 V617F mutation.
• Accelerated erythropoiesis in smokers may increase susceptibility to the JAK2 mutation.
• Further research is warranted to elucidate the precise mechanisms linking smoking, erythropoiesis, and JAK2 mutation development.